» Articles » PMID: 11211310

Effects of Bisphosphonate on the Release of MMP-2 from Cultured Human Osteoblasts

Overview
Specialty General Medicine
Date 2001 Feb 24
PMID 11211310
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Production of matrix metalloproteinases (MMPs) influences bone resorption. We investigated the role of bisphosphonates, potent inhibitors of bone resorption, on the production of MMP-2 from human osteoblasts. Bisphosphonates alone did not influence the amount of MMP-2 produced by human osteoblasts. However, in the presence of physiological concentrations of plasmin, bisphosphonates reduced the amount of MMP-2 in osteoblasts-conditioned media. Furthermore, bisphosphonates treatment induced degradation of MMP-2 in the presence of plasmin. Our results indicated that bisphosphonate, a divalent cation chelator, negatively regulated the longevity of MMP-2 in soluble phase plasmin-containing environment. These findings suggest that bisphosphonates inhibit bone resorption by abrogating MMP-2 protection induced by plasmin-mediated degradation.

Citing Articles

Potential options for managing LOX+ ER- breast cancer patients.

Han Y, Lian S, Cui X, Meng K, Gyorffy B, Jin T Oncotarget. 2016; 7(22):32893-901.

PMID: 27147578 PMC: 5078060. DOI: 10.18632/oncotarget.9073.


Risedronate inhibits human osteosarcoma cell invasion.

Xin Z, Kim Y, Jung S J Exp Clin Cancer Res. 2009; 28:105.

PMID: 19624845 PMC: 2729740. DOI: 10.1186/1756-9966-28-105.


Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women.

Luo X, Guo L, Shan P, Xie H, Wu X, Zhang H Osteoporos Int. 2005; 17(4):521-6.

PMID: 16365830 DOI: 10.1007/s00198-005-0017-6.